 Nick Levinsky
Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glycoproteins | 2 | 2020 | 355 | 0.660 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2019 | 44 | 0.640 |
Why?
| | Reperfusion Injury | 2 | 2021 | 300 | 0.630 |
Why?
| | Intestines | 2 | 2021 | 358 | 0.620 |
Why?
| | Carcinoma, Signet Ring Cell | 1 | 2019 | 17 | 0.600 |
Why?
| | Appendiceal Neoplasms | 1 | 2019 | 28 | 0.600 |
Why?
| | Prescription Drugs | 1 | 2020 | 111 | 0.590 |
Why?
| | Neoadjuvant Therapy | 2 | 2019 | 463 | 0.580 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2019 | 67 | 0.580 |
Why?
| | Esophagectomy | 1 | 2019 | 135 | 0.560 |
Why?
| | Neutrophils | 3 | 2021 | 1134 | 0.530 |
Why?
| | Time-to-Treatment | 1 | 2019 | 245 | 0.510 |
Why?
| | Esophageal Neoplasms | 1 | 2019 | 349 | 0.450 |
Why?
| | Adenocarcinoma | 1 | 2019 | 931 | 0.360 |
Why?
| | Opioid-Related Disorders | 1 | 2020 | 601 | 0.360 |
Why?
| | Pancreatectomy | 3 | 2017 | 285 | 0.290 |
Why?
| | Pancreaticoduodenectomy | 4 | 2017 | 135 | 0.270 |
Why?
| | Lung Neoplasms | 1 | 2020 | 2642 | 0.260 |
Why?
| | Salvage Therapy | 2 | 2019 | 162 | 0.250 |
Why?
| | Pancreatitis, Chronic | 2 | 2016 | 63 | 0.220 |
Why?
| | Databases, Factual | 2 | 2019 | 1486 | 0.200 |
Why?
| | Retrospective Studies | 9 | 2020 | 17101 | 0.180 |
Why?
| | Mesenteric Ischemia | 1 | 2021 | 2 | 0.180 |
Why?
| | Analgesics, Opioid | 2 | 2020 | 1143 | 0.170 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2021 | 57 | 0.160 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2021 | 89 | 0.160 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2021 | 191 | 0.160 |
Why?
| | Colorectal Surgery | 1 | 2019 | 27 | 0.150 |
Why?
| | Survival Rate | 3 | 2019 | 2092 | 0.150 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2019 | 162 | 0.150 |
Why?
| | Peritoneal Neoplasms | 1 | 2019 | 103 | 0.140 |
Why?
| | Anti-Infective Agents | 1 | 2021 | 242 | 0.140 |
Why?
| | Mice, Knockout | 3 | 2021 | 3125 | 0.140 |
Why?
| | Shock, Hemorrhagic | 1 | 2021 | 201 | 0.140 |
Why?
| | Pancreatic Neoplasms | 2 | 2017 | 927 | 0.140 |
Why?
| | Acute Lung Injury | 1 | 2021 | 303 | 0.140 |
Why?
| | Elective Surgical Procedures | 1 | 2019 | 201 | 0.130 |
Why?
| | Up-Regulation | 1 | 2021 | 852 | 0.130 |
Why?
| | Jejunostomy | 1 | 2017 | 13 | 0.130 |
Why?
| | Pancreatitis, Acute Necrotizing | 1 | 2017 | 14 | 0.130 |
Why?
| | Sepsis | 2 | 2021 | 641 | 0.130 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2016 | 27 | 0.120 |
Why?
| | Reoperation | 2 | 2016 | 631 | 0.120 |
Why?
| | Aged | 8 | 2019 | 25947 | 0.120 |
Why?
| | Duodenal Neoplasms | 1 | 2016 | 26 | 0.120 |
Why?
| | Ampulla of Vater | 1 | 2016 | 39 | 0.120 |
Why?
| | Prognosis | 3 | 2019 | 4293 | 0.120 |
Why?
| | Middle Aged | 10 | 2021 | 35928 | 0.120 |
Why?
| | NF-kappa B | 1 | 2019 | 662 | 0.120 |
Why?
| | Male | 12 | 2021 | 72406 | 0.110 |
Why?
| | Mice, Inbred C57BL | 3 | 2021 | 5997 | 0.110 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2015 | 67 | 0.110 |
Why?
| | Female | 12 | 2021 | 78376 | 0.100 |
Why?
| | Cause of Death | 1 | 2016 | 472 | 0.100 |
Why?
| | Length of Stay | 1 | 2019 | 1337 | 0.100 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1268 | 0.100 |
Why?
| | Treatment Outcome | 5 | 2019 | 11695 | 0.100 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2016 | 292 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1958 | 0.090 |
Why?
| | Acute Kidney Injury | 1 | 2020 | 866 | 0.090 |
Why?
| | United States | 2 | 2019 | 15988 | 0.090 |
Why?
| | Colorectal Neoplasms | 1 | 2019 | 848 | 0.090 |
Why?
| | Time Factors | 2 | 2019 | 7183 | 0.080 |
Why?
| | Apoptosis | 1 | 2019 | 2430 | 0.080 |
Why?
| | Mice | 4 | 2021 | 18365 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 1141 | 0.080 |
Why?
| | Appendectomy | 1 | 2010 | 89 | 0.080 |
Why?
| | Humans | 11 | 2021 | 144957 | 0.070 |
Why?
| | Appendicitis | 1 | 2010 | 148 | 0.070 |
Why?
| | Animals | 5 | 2021 | 38109 | 0.070 |
Why?
| | Postoperative Complications | 2 | 2017 | 2920 | 0.070 |
Why?
| | Health Care Costs | 1 | 2010 | 427 | 0.060 |
Why?
| | Signal Transduction | 1 | 2019 | 5233 | 0.060 |
Why?
| | Risk Factors | 1 | 2019 | 10792 | 0.060 |
Why?
| | Cost-Benefit Analysis | 2 | 2019 | 636 | 0.050 |
Why?
| | Occludin | 1 | 2021 | 11 | 0.040 |
Why?
| | Glycocalyx | 1 | 2021 | 30 | 0.040 |
Why?
| | Cell Membrane Permeability | 1 | 2021 | 85 | 0.040 |
Why?
| | Peroxidase | 1 | 2021 | 168 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2021 | 4569 | 0.040 |
Why?
| | Cadherins | 1 | 2021 | 201 | 0.040 |
Why?
| | Hospitalization | 1 | 2010 | 2434 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2010 | 2738 | 0.040 |
Why?
| | Peritonitis | 1 | 2020 | 84 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 149 | 0.040 |
Why?
| | Age Factors | 2 | 2016 | 3335 | 0.040 |
Why?
| | Bone Marrow Transplantation | 1 | 2020 | 294 | 0.040 |
Why?
| | Swine | 1 | 2021 | 833 | 0.040 |
Why?
| | Statistics, Nonparametric | 1 | 2019 | 427 | 0.040 |
Why?
| | Intubation, Intratracheal | 1 | 2021 | 320 | 0.030 |
Why?
| | Risk Assessment | 2 | 2019 | 3676 | 0.030 |
Why?
| | Propensity Score | 1 | 2019 | 367 | 0.030 |
Why?
| | Organoplatinum Compounds | 1 | 2017 | 66 | 0.030 |
Why?
| | Pain Measurement | 1 | 2019 | 555 | 0.030 |
Why?
| | Erlotinib Hydrochloride | 1 | 2017 | 72 | 0.030 |
Why?
| | Leucovorin | 1 | 2017 | 101 | 0.030 |
Why?
| | CA-19-9 Antigen | 1 | 2017 | 34 | 0.030 |
Why?
| | Anastomosis, Surgical | 1 | 2017 | 157 | 0.030 |
Why?
| | Albumins | 1 | 2017 | 118 | 0.030 |
Why?
| | Blood Loss, Surgical | 1 | 2017 | 112 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2021 | 708 | 0.030 |
Why?
| | Adult | 5 | 2021 | 40506 | 0.030 |
Why?
| | Fluorouracil | 1 | 2017 | 235 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2017 | 189 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2016 | 333 | 0.030 |
Why?
| | Paclitaxel | 1 | 2017 | 256 | 0.030 |
Why?
| | Deoxycytidine | 1 | 2017 | 221 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 421 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 870 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2021 | 1126 | 0.030 |
Why?
| | Cohort Studies | 2 | 2019 | 5965 | 0.030 |
Why?
| | Pancreas | 1 | 2017 | 342 | 0.030 |
Why?
| | Transplantation, Autologous | 1 | 2015 | 292 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1077 | 0.020 |
Why?
| | Cytokines | 1 | 2021 | 2065 | 0.020 |
Why?
| | Recurrence | 1 | 2016 | 1135 | 0.020 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 359 | 0.020 |
Why?
| | Patient Selection | 1 | 2016 | 719 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 2365 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2020 | 2609 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2021 | 1915 | 0.020 |
Why?
| | Sex Factors | 1 | 2016 | 2114 | 0.020 |
Why?
| | Inflammation | 1 | 2021 | 2880 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 7997 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2925 | 0.020 |
Why?
| | Lung | 1 | 2021 | 4109 | 0.020 |
Why?
| | Young Adult | 2 | 2015 | 14126 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2015 | 5417 | 0.010 |
Why?
| | Laparoscopy | 1 | 2010 | 475 | 0.010 |
Why?
| | Adolescent | 2 | 2015 | 22453 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2015 | 8279 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 2010 | 2313 | 0.010 |
Why?
|
|
Levinsky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|